Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

Niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the study population compared to placebo.